FrancophonIA/ELRC3.0 huggingface dataset:
English: Rare (may affect up to 1 in 1,000 people):
Slovenian: Redki (pojavijo se lahko pri največ 1 od 1.000 ljudi):
English: A dental examination with appropriate preventive dentistry should be considered prior to treatment with oral bisphosphonates in patients with poor dental status.
Slovenian: Pred začetkom zdravljenja s peroralnimi bisfosfonati naj bolniki s slabim stanjem zob po potrebi opravijo preventivni zobozdravniški pregled.
English: What is VANTAVO?
Slovenian: Kaj je zdravilo VANTAVO?
English: Your doctor has prescribed VANTAVO to treat your osteoporosis and because you are at risk of vitamin D insufficiency.
Slovenian: Zdravnik vam je predpisal zdravilo VANTAVO za zdravljenje osteoporoze in zato, ker pri vas obstaja tveganje za pomanjkanje vitamina D. Zdravilo zmanjša tveganje za zlome hrbtenice in za zlome kolka pri ženskah po menopavzi.
English: How to take VANTAVO
Slovenian: Kako jemati zdravilo VANTAVO
English: VANTAVO 70 mg/5,600 IU tablets EU/1/09/572/006 - 2 tablets EU/1/09/572/007 - 4 tablets EU/1/09/572/008 - 12 tablets
Slovenian: VANTAVO 70 mg/5.600 i.e. tablete EU/1/09/572/006 - 2 tableti EU/1/09/572/007 - 4 tablete EU/1/09/572/008 - 12 tablet
English: Broken bones usually occur at the hip, spine, or wrist and can lead not only to pain but also to considerable problems like stooped posture (‘dowager's hump') and loss of mobility.
Slovenian: Poleg bolečin lahko ti zlomi povzročijo tudi znatne težave, kot sta sključena drža (grba) in izguba gibljivosti.
English: Osteonecrosis of the jaw
Slovenian: Osteonekroza čeljusti
English: Very common musculoskeletal (bone, muscle or joint) pain which is sometimes severe Common joint swelling Rare osteonecrosis of the jaw
Slovenian: Zelo pogosti mišično-skeletne bolečine (v kosteh, mišicah ali sklepih), ki so včasih hude
English: The percentage of patients with vitamin D deficiency (serum 25-hydroxyvitamin D  22.5 nmol/l [ 9 ng/ml]) was significantly reduced by 92 % with VANTAVO (70 mg/2800 IU) vs. alendronate-only (1 % vs 13 %, respectively).
Slovenian: Delež bolnic s pomanjkanjem vitamina D (serumski 25-hidroksivitamin D < 22,5 nmol/l [< 9 ng/ml]) je bil v skupini, ki je prejemala zdravilo VANTAVO (70 mg/2.800 i.e.), pomembno nižji (za 92 %) kot v skupini, ki je prejemala le alendronat (1 % oz. 13 %).
English: There is important additional information about how to take VANTAVO in the package leaflet.
Slovenian: V navodilu za uporabo so pomembne dodatne informacije o jemanju zdravila VANTAVO.
English: VANTAVO 70 mg/2800 IU tablets VANTAVO 70 mg/5,600 IU tablets
Slovenian: VANTAVO 70 mg/2.800 i.e. tablete VANTAVO 70 mg/5.600 i.e. tablete
English: VANTAVO 70 mg/2,800 IU tablets are available in packs containing 2, 4, 6 or 12 tablets.
Slovenian: VANTAVO 70 mg/2.800 i.e tablete so na voljo v pakiranjih, ki vsebujejo 2, 4, 6 ali 12 tablet.
English: VANTAVO 70 mg/5,600 IU tablets are available in packs containing 2, 4 or 12 tablets.
Slovenian: VANTAVO 70 mg/5.600 i.e tablete so na voljo v pakiranjih, ki vsebujejo 2, 4 ali 12 tablet.
English: 2) After getting up for the day and before taking any food, drink, or other medicine, swallow your
Slovenian: 2) Potem, ko zjutraj vstanete in še preden zaužijete prvo hrano, pijačo ali katero koli drugo zdravilo, pogoltnite celo tableto VANTAVO samo s polnim kozarcem vode (ne mineralne vode)
English: Always take VANTAVO exactly as your doctor or pharmacist has told you.
Slovenian: Pri jemanju zdravila VANTAVO natančno upoštevajte navodila zdravnika ali farmacevta.
English: These side effects may worsen if patients continue to take VANTAVO after developing these symptoms.
Slovenian: Če potem, ko so se že pojavili neželeni učinki, bolnik nadaljuje z jemanjem zdravila VANTAVO, se lahko neželeni učinki še poslabšajo.
English: You should have routine dental check-ups throughout your treatment and you should contact your doctor or dentist if you experience any problems with your mouth or teeth such as loose teeth, pain or swelling.
Slovenian: V primeru kakršnih koli težav v ustih ali z zobmi, kot so majavost zob, bolečina ali otekanje, se morate posvetovati z zdravnikom ali zobozdravnikom.
English: Oesophageal reactions (sometimes severe and requiring hospitalisation), such as oesophagitis, oesophageal ulcers and oesophageal erosions, rarely followed by oesophageal stricture, have been reported in patients receiving alendronate.
Slovenian: Pri bolnikih, ki so jemali alendronat, so poročali o neželenih pojavih v požiralniku, kot so ezofagitis, razjede in erozije požiralnika, ki jim je redko sledila striktura požiralnika.
English: Relative to an intravenous reference dose, the oral mean bioavailability of alendronate in women was 0.64 % for doses ranging from 5 to 70 mg when administered after an overnight fast and two hours before a standardised breakfast.
Slovenian: Po peroralni uporabi (zjutraj na tešče in dve uri pred standardiziranim zajtrkom) je bila pri ženskah povprečna biološka uporabnost alendronata za odmerke od 5 do 70 mg v primerjavi z intravenskim referenčnim odmerkom 0,64 %.
English: Hypocalcaemia, hypophosphataemia and upper gastrointestinal adverse reactions, such as upset stomach, heartburn, oesophagitis, gastritis, or ulcer, may result from oral overdose.
Slovenian: Zaradi prekomernih peroralnih odmerkov lahko pride do hipokalciemije, hipofosfatemije in neželenih učinkov v zgornjem delu prebavil, kot so razdraženost želodca, zgaga, ezofagitis, gastritis ali razjeda.
English: Very rare (may affect up to 1 in 10,000 people):
Slovenian: Zelo redki (pojavijo se lahko pri največ 1 od 10.000 bolnikov):
English: Common asthenia
Slovenian: Očesne bolezni
English: Ear and labyrinth disorders
Slovenian: Ušesne bolezni vključno z motnjami labirinta
English: • headache; dizziness,
Slovenian: • glavobol, omotica
English: Physicians should therefore be alert to any signs or symptoms signalling a possible oesophageal reaction and patients should be instructed to discontinue alendronate and seek medical attention if they develop symptoms of oesophageal irritation such as dysphagia, pain on swallowing or retrosternal pain or new or worsening heartburn (see section 4.8).
Slovenian: Bolniku mora naročiti, naj v primeru simptomov draženja požiralnika, kot so disfagija, bolečine pri požiranju ali retrosternalna bolečina, pojav zgage ali poslabšanje le-te, prekine zdravljenje z alendronatom in poišče zdravniško pomoč (glejte poglavje 4.8).
English: Patients in the Vitamin D3 2,800 group received VANTAVO (70 mg/2,800 IU) (n=299) and patients in the Vitamin D3 5,600 group received VANTAVO (70 mg/2,800 IU) plus an additional 2,800 IU vitamin D3 (n=309) once a week; additional vitamin D supplements were allowed.
Slovenian: Bolnice v skupini "Vitamin D3 2.800" so prejemale zdravilo VANTAVO (70 mg/2.800 i.e.) (n = 299), bolnice v skupini "Vitamin D3 5.600" pa so prejemale zdravilo VANTAVO (70 mg/2.800 i.e.) in dodatnih 2.800 i.e. vitamina D3 (n = 309) enkrat tedensko; dovoljeni so bili tudi drugi dodatki vitamina D. Po 24 tednih zdravljenja so bile povprečne vrednosti 25-hidroksivitamina D v serumu v skupini "Vitamin D3 5.600" pomembno višje (69 nmol/l [27,6 ng/ml]) kot v skupini "Vitamin D3 2.800" (64 nmol/l [25,5 ng/ml]).
English: VANTAVO 70 mg/5,600 IU tablets are available as modified rectangle-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘270' on the other.
Slovenian: VANTAVO 70 mg/5.600 i.e. tablete imajo obliko modificiranega pravokotnika, so bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘270'.
English: Every week, take one VANTAVO tablet on your chosen day.
Slovenian: 1) Izberite dan v tednu, ki vam najbolj ustreza, nato pa vsak teden na izbrani dan vzemite eno tableto VANTAVO.
English: VANTAVO 70 mg/2800 IU tablets are available as modified capsule-shaped, white to off-white tablets marked with an outline of a bone image on one side and ‘710' on the other.
Slovenian: VANTAVO 70 mg/2.800 i.e. tablete imajo obliko modificirane kapsule, so bele do skoraj bele barve, na eni strani imajo vtisnjen obris kosti, na drugi pa oznako ‘710'.
English: Because there is a potential for worsening of the underlying disease, caution should be used when alendronate is given to patients with active upper gastrointestinal problems, such as dysphagia, oesophageal disease, gastritis, duodenitis, ulcers, or with a recent history (within the previous year) of major gastrointestinal disease such as peptic ulcer, or active gastrointestinal bleeding, or surgery of the upper gastrointestinal tract other than pyloroplasty (see section 4.3).
Slovenian: Previdnost je potrebna tudi pri bolnikih, ki so imeli v zadnjem obdobju (v preteklem letu) hujše bolezni prebavil, kot na primer peptično razjedo, aktivno krvavitev iz prebavil ali kirurški poseg (razen piloroplastike) v zgornjem delu prebavil (glejte poglavje 4.3).
English: VANTAVO 70 mg/2800 IU tabletsVANTAVO 70 mg/5,600 IU tablets Alendronic acid / colecalciferol
Slovenian: VANTAVO 70 mg/2.800 i.e. tablete VANTAVO 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
English: VANTAVO 70 mg/2,800 IU tablets Aluminium/aluminium blisters, in cartons containing 2, 4, 6 or 12 tablets.
Slovenian: VANTAVO 70 mg/2.800 i.e. tablete Pretisni omoti (aluminij/aluminij) v škatlah, ki vsebujejo 2, 4, 6 ali 12 tablet.
English: The most commonly reported adverse reactions are upper gastrointestinal adverse reactions including abdominal pain, dyspepsia, oesophageal ulcer, dysphagia, abdominal distension and acid regurgitation
Slovenian: Najbolj pogosto so poročali o neželenih učinkih v zgornjem delu prebavil, vključno z bolečino v trebuhu, dispepsijo, razjedo požiralnika, disfagijo, napetim trebuhom in refluksom kisline (> 1 %).
English: insufficiency (serum 25-hydroxyvitamin D < 37.5 nmol/l [< 15 ng/ml]) was significantly reduced by 62.5 % with VANTAVO (70 mg/2800 IU) vs. alendronate-only (12 % vs. 32 %, respectively), through week 15.
Slovenian: Delež bolnic s pomanjkanjem vitamina D (serumski 25-hidroksivitamin D < 37,5 nmol/l [< 15 ng/ml]) je bil v skupini, ki je prejemala zdravilo VANTAVO (70 mg/2.800 i.e.), v 15. tednu pomembno nižji (za 62,5 %) kot v skupini, ki je prejemala le alendronat (12 % oz. 32 %).
English: Each VANTAVO 70 mg/2,800 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 70 micrograms (2800 IU) colecalciferol (vitamin D3).
Slovenian: Ena VANTAVO 70 mg/2.800 i.e. tableta vsebuje 70 mg alendronske kisline (v obliki natrijevega trihidrata) in 70 mikrogramov (2.800 i.e.) holekalciferola (vitamina D3).
English: Uncommon (may affect up to 1 in 100 people):
Slovenian: Občasni (pojavijo se lahko pri največ 1 od 100 ljudi):
English: VANTAVO 70 mg/5,600 IU tablets Aluminium/aluminium blisters, in cartons containing 2, 4 or 12 tablets.
Slovenian: VANTAVO 70 mg/5.600 i.e. tablete Pretisni omoti (aluminij/aluminij) v škatlah, ki vsebujejo 2, 4 ali 12 tablet.
English: Each VANTAVO 70 mg/5,600 IU tablet contains 70 mg alendronic acid (as sodium trihydrate) and 140 micrograms (5,600 IU) colecalciferol (vitamin D3)
Slovenian: Ena VANTAVO 70 mg/5.600 i.e. tableta vsebuje 70 mg alendronske kisline (v obliki natrijevega trihidrata) in 140 mikrogramov (5.600 i.e.) holekalciferola (vitamina D3).
English: 70 mg/5600 IU tablets alendronic acid/colecalciferol
Slovenian: 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
English: Common alopecia
Slovenian: Pogosti alopecija †, pruritus
English: Very common (may affect more than 1 in 10 people):
Slovenian: Pogosti (pojavijo se lahko pri največ 1 od 10 ljudi):
English: Pharmacokinetic properties
Slovenian: 5.2 Farmakokinetične lastnosti
English: VANTAVO 70 mg/5600 IU tablets alendronic acid /colecalciferol
Slovenian: VANTAVO 70 mg/5.600 i.e. tablete alendronska kislina/holekalciferol
English: BLISTER FOR VANTAVO 70 mg/2,800 IU
Slovenian: PRETISNI OMOT ZA ZDRAVILO VANTAVO 70 mg/2.800 i.e.
English: Common headache, dizziness Uncommon dysgeusia
Slovenian: Pogosti glavobol, omotica
English: Batch
Slovenian: ČET
English: Each tablet contains 70 mg alendronic acid (as sodium trihydrate) and 140 micrograms (5,600 IU) colecalciferol (vitamin D3).
Slovenian: Ena tableta vsebuje 70 mg alendronske kisline (v obliki natrijevega trihidrata) in 140 mikrogramov (5.600 i.e.) holekalciferola (vitamin D3).
English: In patients with these conditions, serum calcium and symptoms of hypocalcaemia should be monitored during therapy with VANTAVO.
Slovenian: Količina vitamina D v zdravilu VANTAVO ne zadošča za odpravo pomanjkanja vitamina D. Pri bolnikih s temi boleznimi je treba med zdravljenjem z zdravilom VANTAVO spremljati vrednost kalcija v serumu in simptome hipokalciemije.
English: Bone, joint, and/or muscle pain has been reported in patients taking bisphosphonates.
Slovenian: Pri bolnikih, ki so jemali bisfosfonate, so poročali o bolečinah v kosteh, sklepih in/ali mišicah.
English: For oral use.
Slovenian: Način uporabe peroralna uporaba
English: Each tablet contains 70 mg of alendronic acid (as sodium trihydrate) and 70 micrograms (2800 IU) colecalciferol (vitamin D3.
Slovenian: Ena tableta vsebuje 70 mg alendronske kisline (v obliki natrijevega trihidrata) in 70 mikrogramov (2.800 i.e.) holekalciferola (vitamin D3).
English: EXPIRY DATE
Slovenian: Občasni disgevzija
English: Atypical subtrochanteric and diaphyseal femoral fractures have been reported with bisphosphonate therapy, primarily in patients receiving long-term treatment for osteoporosis.
Slovenian: Pri zdravljenju z bisfosfonati, še posebej pri dolgotrajnem zdravljenju osteoporoze, so poročali o atipičnih subtrohanternih zlomih stegnenice in zlomih diafize stegnenice.
English: VANTAVO 70 mg/2800 IU tablets alendronic acid /colecalciferol
Slovenian: VANTAVO 70 mg/2.800 i.e. tablete alendronska kislina/holekalciferol
English: Oral use.
Slovenian: Navodilo za uporabo
English: Contact your doctor and dentist if you experience such symptoms,
Slovenian: V primeru takšnih simptomov se posvetujte z zdravnikom ali zobozdravnikom.
English: BLISTER FOR VANTAVO 70 mg/5,600 IU
Slovenian: PRETISNI OMOT ZA ZDRAVILO VANTAVO 70 mg/5.600 i.e.
English: 70 mg/2800 IU tablets alendronic acid/colecalciferol
Slovenian: 70 mg/2.800 i.e. tablete alendronska kislina/holekalciferol
English: • bone, muscle and/or joint pain which is severe.
Slovenian: • huda bolečina v kosteh, mišicah in/ali sklepih
English: The recommended dose is 400 mg once a month.
Slovenian: Priporočeni odmerek je 400 mg enkrat na mesec.
English: In one main study involving adults whose disease had already been stabilised on treatment with aripiprazole taken by mouth, 22 out of the 265 patients (8.3%) treated with Abilify Maintena had symptoms coming back within 26 weeks, compared with 21 out of 266 (7.9%) patients treated with aripiprazole taken by mouth.
Slovenian: V eni glavni študiji, v katero so bili vključeni odrasli, pri katerih je bila bolezen že stabilizirana med zdravljenjem s peroralnim aripiprazolom, so se simptomi v 26 tednih ponovno pojavili pri 22 od 265 (8,3 %) bolnikov, zdravljenih z zdravilom Abilify Maintena, in pri 21 od 266 (7,9 %) bolnikov, zdravljenih s peroralnim aripiprazolom.
English: Schizophrenia is a mental illness with a number of symptoms, including disorganised thinking and speech, hallucinations (hearing or seeing things that are not there), suspiciousness and delusions (false beliefs).
Slovenian: Shizofrenija je duševna bolezen s številnimi simptomi, ki vključujejo neorganizirano mišljenje in govor, halucinacije (bolnik vidi in sliši stvari, ki jih ni), sumničavost ter blodnje (zmotna prepričanja).
English: The full EPAR for Abilify Maintena can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Abilify Maintena je na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: ‘Prolonged release' means that the active substance is released slowly over a few weeks after being injected.
Slovenian: Podaljšano sproščanje pomeni, da se zdravilna učinkovina počasi sprošča nekaj tednov po injiciranju.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Abilify Maintena's benefits are greater than its risks and recommended that it be approved for use in the EU.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da so koristi zdravila Abilify Maintena večje od z njim povezanih tveganj, in priporočil, da se odobri za uporabo v EU.
English: This is a summary of the European public assessment report (EPAR) for Abilify Maintena.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Abilify Maintena.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Abilify Maintena on 15 November 2013.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Abilify Maintena, veljavno po vsej Evropski uniji, izdala 15. novembra 2013.
English: Its exact mechanism of action is unknown, but it attaches to several receptors on the surface of nerve cells in the brain.
Slovenian: Natančen mehanizem delovanja zdravila sicer ni znan, znano pa je, da se zdravilo veže na več receptorjev na površini živčnih celic v možganih.
English: This disrupts signals transmitted between brain cells by ‘neurotransmitters', chemicals that allow nerve cells to communicate with each other.
Slovenian: S tem se prekine prenos signalov med možganskimi celicami prek živčnih prenašalcev, tj. kemičnih snovi, ki omogočajo sporazumevanje med celicami.
English: Abilify Maintena is available as a powder (300 mg and 400 mg) and solvent to be made into a prolonged-release suspension for injection.
Slovenian: Zdravilo Abilify Maintena je na voljo v obliki praška (300 mg in 400 mg) in vehikla za pripravo suspenzije za injiciranje s podaljšanim sproščanjem.
English: Abilify Maintena aripiprazole
Slovenian: Abilify Maintena aripiprazol
English: Since dopamine and 5hydroxytryptamine are involved in schizophrenia, aripiprazole helps to normalise the activity of the brain, reducing psychotic symptoms and preventing them from returning.
Slovenian: Ker dopamin in 5-hidroksitriptamin sodelujeta v bolezenskem procesu shizofrenije, aripiprazol pomaga normalizirati delovanje možganov, zmanjšati psihotične simptome in preprečiti njihov ponoven pojav.
English: Treatment beyond 2 weeks with medicines that speed up the breakdown of aripiprazole should be avoided.
Slovenian: Izogibati se je treba več kot dvotedenskemu zdravljenju z zdravili, ki pospešujejo razgradnjo aripiprazola.
English: Aripiprazole is thought to act mainly by being a ‘partial agonist' for the receptors for the neurotransmitters dopamine and 5-hydroxytryptamine (also called serotonin).
Slovenian: Aripiprazol domnevno deluje predvsem kot delni agonist za receptorje za živčna prenašalca dopamin in 5-hidroksitriptamin (imenovanega tudi serotonin).
English: The medicine is given once a month by slow injection into the buttock or deltoid (shoulder) muscle by a doctor or nurse.
Slovenian: Zdravilo se daje enkrat na mesec, tako da ga zdravnik ali medicinska sestra počasi injicira v zadnjično ali deltoidno (ramensko) mišico.
English: The most common side effects with Abilify Maintena (which may affect 5 or more people in 100) are increased weight, akathisia (a constant urge to move), insomnia (difficulty sleeping) and injection site pain.
Slovenian: Najpogostejši neželeni učinki zdravila Abilify Maintena (ki lahko prizadenejo več kot 5 oseb od 100) so povečana telesna masa, akatizija (neprestana potreba po gibanju), nespečnost (težave s spanjem) in bolečina na mestu injiciranja.
English: After the first injection, daily treatment with 10 to 20 mg aripiprazole by mouth should be continued for 2 weeks.
Slovenian: Po prvem injiciranju je treba zdravljenje dva tedna nadaljevati z vsakodnevnim peroralnim 10- do 20-miligramskim odmerkom aripiprazola.
English: What measures are being taken to ensure the safe and effective use of Abilify Maintena?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Abilify Maintena?
English: It is used for the maintenance treatment of schizophrenia in adults whose disease has already been stabilised on treatment with aripiprazole taken by mouth.
Slovenian: Uporablja se za vzdrževalno zdravljenje shizofrenije pri odraslih, pri katerih je bila bolezen stabilizirana med peroralnim zdravljenjem z aripiprazolom.
English: For more information about treatment with Abilify Maintena, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Abilify Maintena preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: A risk management plan has been developed to ensure that Abilify Maintena is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Abilify Maintena je bil pripravljen načrt obvladovanja tveganj.
English: The CHMP noted that Abilify Maintena is as effective as aripiprazole taken by mouth, and has a similar safety profile with the exception of injection pain, which was considered manageable.
Slovenian: Izpostavil je, da je zdravilo Abilify Maintena enako učinkovito kot peroralni aripiprazol in ima tudi podoben varnostni profil, z izjemo bolečine na mestu injiciranja, ki pa je obvladljiva.
English: This means that aripiprazole acts like dopamine and 5-hydroxytryptamine by activating these receptors, but less strongly than the neurotransmitters.
Slovenian: To pomeni, da z aktiviranjem teh receptorjev deluje kot dopamin in 5-hidroksitriptamin, vendar šibkeje kot živčni prenašalci.
English: The Committee considered that the monthly administration may help patients to adhere to their treatment.
Slovenian: Menil je, da bi vsakomesečno dajanje zdravila lahko bolnikom pomagalo, da bi se držali predpisanega zdravljenja.
English: Other information about Abilify Maintena
Slovenian: Druge informacije o zdravilu Abilify Maintena
English: What is Abilify Maintena and what is it used for?
Slovenian: Kaj je zdravilo Abilify Maintena in za kaj se uporablja?
English: For practical information about using Abilify Maintena, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Abilify Maintena naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Abilify Maintena, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: For the full list of all side effects reported with Abilify Maintena, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Abilify Maintena, glejte navodilo za uporabo.
English: The active substance in Abilify Maintena, aripiprazole, is an antipsychotic medicine.
Slovenian: Zdravilna učinkovina zdravila Abilify Maintena, aripiprazol, je antipsihotično zdravilo.
English: What benefits of Abilify Maintena have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Abilify Maintena izkazalo v študijah?
English: What are the risks associated with Abilify Maintena?
Slovenian: Kakšna tveganja so povezana z zdravilom Abilify Maintena?
English: Abilify Maintena is a medicine that contains the active substance aripiprazole.
Slovenian: Abilify Maintena je zdravilo, ki vsebuje zdravilno učinkovino aripiprazol.
English: Why is Abilify Maintena approved?
Slovenian: Zakaj je bilo zdravilo Abilify Maintena odobreno?